DK1100515T3 - Ex vivo-behandling af allogene og xenogene T-celler med pg39-antagonister - Google Patents

Ex vivo-behandling af allogene og xenogene T-celler med pg39-antagonister

Info

Publication number
DK1100515T3
DK1100515T3 DK99944997T DK99944997T DK1100515T3 DK 1100515 T3 DK1100515 T3 DK 1100515T3 DK 99944997 T DK99944997 T DK 99944997T DK 99944997 T DK99944997 T DK 99944997T DK 1100515 T3 DK1100515 T3 DK 1100515T3
Authority
DK
Denmark
Prior art keywords
cells
antagonists
xenogenic
allogeneic
vivo treatment
Prior art date
Application number
DK99944997T
Other languages
English (en)
Inventor
Randolph J Noelle
Bruce R Blazar
Daniel A Vallera
Patricia A Taylor
Original Assignee
Univ Minnesota
Dartmouth College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minnesota, Dartmouth College filed Critical Univ Minnesota
Application granted granted Critical
Publication of DK1100515T3 publication Critical patent/DK1100515T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46434—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/52—CD40, CD40-ligand (CD154)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Materials For Medical Uses (AREA)
DK99944997T 1998-07-30 1999-07-29 Ex vivo-behandling af allogene og xenogene T-celler med pg39-antagonister DK1100515T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12468398A 1998-07-30 1998-07-30

Publications (1)

Publication Number Publication Date
DK1100515T3 true DK1100515T3 (da) 2005-12-12

Family

ID=22416260

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99944997T DK1100515T3 (da) 1998-07-30 1999-07-29 Ex vivo-behandling af allogene og xenogene T-celler med pg39-antagonister

Country Status (14)

Country Link
US (2) US20020048579A1 (da)
EP (2) EP1637146A3 (da)
JP (1) JP4109828B2 (da)
KR (1) KR100711210B1 (da)
CN (1) CN1161129C (da)
AT (1) ATE309808T1 (da)
AU (1) AU764015C (da)
CA (1) CA2338773A1 (da)
DE (1) DE69928407T2 (da)
DK (1) DK1100515T3 (da)
ES (1) ES2252970T3 (da)
HU (1) HUP0103107A2 (da)
NO (1) NO20010488L (da)
WO (1) WO2000006178A1 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8776230B1 (en) * 2001-10-02 2014-07-08 Mcafee, Inc. Master security policy server
US7435592B2 (en) 2003-05-13 2008-10-14 Immunovative Therapies, Ltd. Compositions for allogeneic cell therapy
WO2005021734A2 (en) * 2003-09-02 2005-03-10 University Of Massachussets Generation of hematopoietic chimerism and induction of central tolerance

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5725855A (en) * 1991-04-05 1998-03-10 The United States Of America As Represented By The Department Of Health And Human Services Method of treating tumors with CD8+ -depleted or CD4+ T cell subpopulations
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
US5916560A (en) * 1996-03-20 1999-06-29 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the GP39/CD40 and CTLA4/CD28/B7 pathways and compositions for use therewith

Also Published As

Publication number Publication date
NO20010488D0 (no) 2001-01-29
ES2252970T3 (es) 2006-05-16
WO2000006178A1 (en) 2000-02-10
EP1637146A2 (en) 2006-03-22
DE69928407T2 (de) 2006-08-03
KR20010071078A (ko) 2001-07-28
JP4109828B2 (ja) 2008-07-02
CA2338773A1 (en) 2000-02-10
EP1637146A3 (en) 2008-02-20
US20020022020A1 (en) 2002-02-21
DE69928407D1 (de) 2005-12-22
KR100711210B1 (ko) 2007-04-24
ATE309808T1 (de) 2005-12-15
AU764015B2 (en) 2003-08-07
EP1100515A1 (en) 2001-05-23
NO20010488L (no) 2001-03-27
AU5770399A (en) 2000-02-21
US20020048579A1 (en) 2002-04-25
HUP0103107A2 (hu) 2001-11-28
EP1100515A4 (en) 2003-04-02
EP1100515B1 (en) 2005-11-16
AU764015C (en) 2006-03-16
JP2002521042A (ja) 2002-07-16
CN1161129C (zh) 2004-08-11
CN1319019A (zh) 2001-10-24

Similar Documents

Publication Publication Date Title
DE60229848D1 (de) - und organtransplantationen und unterdrückt apoptose
DK1192185T3 (da) Apo-2L-receptoragonist og CPT-11-synergisme
CY1108815T1 (el) Διαδοχικη χορηγηση cpt-11 και πολυπεπτιδιου apo-2l
DK1226233T3 (da) Multipotente voksne stamceller og fremgangsmåder til isolering heraf
DK0633721T3 (da) Rensning af blodplader med 8-metoxypsoralen
DK1113810T3 (da) Fremgangsmåder til behandling af multipelt myelom og myelom-induceret knogleresorption under anvendelse af antagonister af integrin/receptor-binding
DK0952772T3 (da) Fremgangsmåder til anvendelse af mononukleare phagocytter til at fremme axonal regeneration
WO2002040049A3 (en) Blockade of t cell migration into epithelial gvhd target tissues
ATE514771T1 (de) Haartransplantation
BR9306345A (pt) Métodos para suprimir a habilidade de células-t de um mamífero de proliferar e para suprimir resposta imune composições para uso na supressão da capacidade de células-t de proliferarem e na supressão de resposta imune
NO20023833D0 (no) Modifiserte cytokiner for anvendelse i cancerterapi
DK1100515T3 (da) Ex vivo-behandling af allogene og xenogene T-celler med pg39-antagonister
DK0793503T3 (da) Anvendelse af hepatocyt-vækstfaktor til inducering af profilerering og differentiering af hemotopoietiske celler
DK0697876T3 (da) Xenograftthymus
FI971879A0 (fi) Allogeenisten ja ksenogeenisten proteiinien vasta-aineet, niiden käyttö diagnoosissa ja hoidossa ja menetelmät niiden määrittämiseksi
ATE377965T1 (de) Schälvorrichtung
ATE263833T1 (de) Verwendung von dendritischen zellen-depletierten zusammensetzungen zur verbesserung der transplantation von allogenen hämatopoietischen zellen
DE69434159D1 (de) Allogene und xenogene Transplantation
DE69926997D1 (de) Blutverträgliche zusammensetzung und medizinische vorrichtung unter verwendung derselben
IT1317888B1 (it) Rebbio perfezionato, in particolare per la raccolta di frutti qualiolive, mandorle, pistacchi, caffe' e simili.
ES2153309A1 (es) Dispositivo para el sostenimiento y desplazamiento individual de personas sobre masas liquidas.
UA33888A (uk) Спосіб зменшення імунореактивності алогенного кісткового мозку експериментальних тварин